Over 10,000 results
S-1/A
RAPP
Rapport Therapeutics, Inc.
3 Jun 24
IPO registration (amended)
6:08am
Research and Development Expenses
For the three months ended March 31, | ||||||||||||
2023 | 2024 | Change | ||||||||||
(in thousands) | ||||||||||||
Direct external program expenses: | ||||||||||||
RAP-219 program | $ | 1,117 | $ | 3,901 | $ | 2,784 | ||||||
Preclinical programs | 711 | 3,934 | 3,223 | |||||||||
Internal and unallocated expenses: | ||||||||||||
Personnel-related costs (including stock-based compensation) | 1,940 | 4,017 | 2,077 | |||||||||
Other costs | 131 | 652 | 521 | |||||||||
Total research and development expenses | $ | 3,899 | $ | 12,504 | $ | 8,605 | ||||||
S-1/A
RAPP
Rapport Therapeutics, Inc.
3 Jun 24
IPO registration (amended)
6:08am
Notes to Consolidated Financial Statements
Fair Value Measurements at December 31, 2023: | ||||||||||||||||
Level 1 | Level 2 | Level 3 | Total | |||||||||||||
Assets: | ||||||||||||||||
Cash equivalents: | ||||||||||||||||
Money market funds | $ | 23,441 | $ | — | $ | — | $ | 23,441 | ||||||||
US Treasury bills | — | 23,832 | — | $ | 23,832 | |||||||||||
Short-term investments: | ||||||||||||||||
U.S. Treasury bills and government securities | — | 77,309 | — | $ | 77,309 | |||||||||||
$ | 23,441 | $ | 101,141 | $ | — | $ | 124,582 | |||||||||
Liabilities | ||||||||||||||||
Series B preferred stock tranche right liability | $ | — | $ | — | $ | 4,200 | $ | 4,200 | ||||||||
$ | — | $ | — | $ | 4,200 | $ | 4,200 | |||||||||
S-1/A
RAPP
Rapport Therapeutics, Inc.
3 Jun 24
IPO registration (amended)
6:08am
Right-of-use lease assets and lease liabilities are reported in the Company’s consolidated balance sheets as follows (in thousands):
Period from February 10, 2022 (inception) to December 31, 2022 | Year Ended December 31, 2023 | |||||||
Operating lease | ||||||||
Operating lease right-of-use assets, net | $ | — | $ | 2,084 | ||||
Operating lease right-of-use liabilities, current | — | 670 | ||||||
Operating lease right-of-use liabilities, non-current | — | 1,476 | ||||||
Total operating lease liabilities | $ | — | $ | 2,146 | ||||
S-1/A
RAPP
Rapport Therapeutics, Inc.
3 Jun 24
IPO registration (amended)
6:08am
The components of income tax provision are as follows (in thousands):
Period from February 10, 2022 (inception) to December 31, 2022 | Year Ended December 31, 2023 | |||||||
Components of income tax provision | ||||||||
Current Provision: | ||||||||
Federal | $ | — | $ | — | ||||
State | — | 10 | ||||||
Total current provision | — | 10 | ||||||
Deferred income tax provision (benefit) | — | — | ||||||
Federal | — | — | ||||||
State | — | — | ||||||
Total deferred income tax provision (benefit) | — | — | ||||||
Total provision for (benefit from) income taxes | $ | — | $ | 10 | ||||
S-1/A
RAPP
Rapport Therapeutics, Inc.
3 Jun 24
IPO registration (amended)
6:08am
Short-term investments consisted of the following (in thousands):
December 31, 2023 | ||||||||||||||||
Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value | |||||||||||||
Short-term investments: | ||||||||||||||||
U.S. Treasury bills and government securities | $ | 77,305 | $ | 4 | $ | — | $ | 77,309 | ||||||||
$ | 77,305 | $ | 4 | $ | — | $ | 77,309 | |||||||||
March 31, 2024 | ||||||||||||||||
Amortized Cost | Unrealized Gains | Unrealized Losses | Fair Value | |||||||||||||
Short-term investments: | ||||||||||||||||
U.S. Treasury bills, government securities, and government agency securities | $ | 119,137 | $ | — | $ | (160) | $ | 118,977 | ||||||||
$ | 119,137 | $ | — | $ | (160) | $ | 118,977 | |||||||||
S-1/A
anh83cxfqd
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
ic4yh8
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
g7eei zc1mt9tiykw0ba
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
0x0pfnv
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
igz i1dvlhek6iwfoo
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
zpukheb8huq1
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
ekwi8 nh48fxpv4e8yc
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
qparbawn
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
xij7dj 2r
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
mi6r1
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
rsujkcu3
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
va77w 86aq
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
1i2ehdg5vur
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
ai5nnfzt
3 Jun 24
IPO registration (amended)
6:08am
S-1/A
tfhewy2 wgzans
3 Jun 24
IPO registration (amended)
6:08am